226 related articles for article (PubMed ID: 27864450)
21. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma.
Kang HJ; Lim HJ; Park JS; Cho YJ; Yoon HI; Chung JH; Lee JH; Lee CT
Respir Med; 2014 Feb; 108(2):388-94. PubMed ID: 24361161
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Jin J; Liu BZ; Wu ZM
J Cancer Res Ther; 2015 Nov; 11 Suppl():C271-4. PubMed ID: 26612451
[TBL] [Abstract][Full Text] [Related]
23. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer.
Ujiie H; Kato T; Lee D; Hu HP; Fujino K; Kaji M; Kaga K; Matsui Y; Yasufuku K
Int J Oncol; 2017 Jun; 50(6):2154-2170. PubMed ID: 28498455
[TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
26. Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.
Pan SH; Su KY; Spiessens B; Kusuma N; Delahaye NF; Gruselle O; Myo A; de Creus A; Louahed J; Chang GC; Yu SL; Yang PC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e212-e223. PubMed ID: 27519286
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
28. LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.
Wang L; Meng Y; Zhang QY
BMC Cancer; 2019 Apr; 19(1):293. PubMed ID: 30940109
[TBL] [Abstract][Full Text] [Related]
29. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
Xu L; Lei J; Wang QZ; Li J; Wu L
Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
32. Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.
Wang H; Schabath MB; Liu Y; Han Y; Li Q; Gillies RJ; Ye Z
Eur J Radiol; 2016 Nov; 85(11):1934-1940. PubMed ID: 27776643
[TBL] [Abstract][Full Text] [Related]
33. Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?
Halpenny DF; Riely GJ; Hayes S; Yu H; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2014 Nov; 86(2):190-4. PubMed ID: 25312988
[TBL] [Abstract][Full Text] [Related]
34. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
35. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
36. WDR62 overexpression is associated with a poor prognosis in patients with lung adenocarcinoma.
Shinmura K; Kato H; Kawanishi Y; Igarashi H; Inoue Y; Yoshimura K; Nakamura S; Fujita H; Funai K; Tanahashi M; Niwa H; Ogawa H; Sugimura H
Mol Carcinog; 2017 Aug; 56(8):1984-1991. PubMed ID: 28277612
[TBL] [Abstract][Full Text] [Related]
37. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
38. Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.
Kobayashi M; Sakakibara T; Inoue A; Fukuhara T; Sasano H; Ichinose M; Nukiwa T
Respir Investig; 2014 Jan; 52(1):49-56. PubMed ID: 24388371
[TBL] [Abstract][Full Text] [Related]
39. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
40. Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.
Zito Marino F; Liguori G; Aquino G; La Mantia E; Bosari S; Ferrero S; Rosso L; Gaudioso G; De Rosa N; Scrima M; Martucci N; La Rocca A; Normanno N; Morabito A; Rocco G; Botti G; Franco R
PLoS One; 2015; 10(9):e0139264. PubMed ID: 26422230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
